Novo Nordisk Unveils Wegovy Weight-Loss Pill in US at Lower Price

Novo Nordisk has launched the first GLP-1 weight-loss pill in the US, intensifying competition. The once-daily Wegovy pill is priced well below injectable versions, accelerating a sector-wide price war. It is the first approved pill that mimics the GLP-1 hormone to reduce appetite. Self-paying patients can access the starting dose for $149 a month, or $5 a day. Higher doses will rise to between $199 and $299 monthly. Insured patients may pay as little as $25 a month. Analysts say prices are far lower than typical $1,000-a-month injections. The launch lifted Novo’s shares despite strong rivalry from Eli Lilly. The pill is now available in major US pharmacies and telehealth platforms. Regulators in the UK are reviewing approval later this year.